• Regulatory NewsRegulatory News

    EMA Recommends Suspending Certain Gadolinium Contrast Agents

    The European Medicines Agency (EMA) on Friday said it plans to suspend the marketing authorization for three gadolinium contrast agents and restrict the use of others after a review by the agency's Pharmacovigilance Risk Assessment Committee (PRAC) confirmed evidence of gadolinium accumulation in patients' brains months after being injected. EMA says the move is a precautionary measure, as there is currently no evidence that gadolinium accumulation in the brain poses a h...